ClinicalTrials.gov record
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov ID: NCT03170960
Public ClinicalTrials.gov record NCT03170960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
ClinicalTrials.gov public records Last synced May 5, 2026, 7:46 AM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT03170960
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Exelixis
- Industry
- Enrollment
- 914 participants
Conditions and interventions
Conditions
- Castration-resistant Prostate Cancer
- Colorectal Cancer
- Differentiated Thyroid Cancer
- Endometrial Cancer
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Head and Neck Cancer
- Hepatocellular Carcinoma
- Lower Esophageal Cancer
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Triple Negative Breast Cancer
- Urothelial Carcinoma
Interventions
- atezolizumab Drug
- cabozantinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 4, 2017
- Primary completion
- Feb 20, 2023
- Completion
- Sep 29, 2027
- Last update posted
- Aug 16, 2025
2017 – 2027
United States locations
- U.S. sites
- 57
- U.S. states
- 27
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #53 | Gilbert | Arizona | 85234 | — |
| Exelixis Clinical Site #18 | Phoenix | Arizona | 85054 | — |
| Exelixis Clinical Site #1 | Duarte | California | 91010 | — |
| Exelixis Clinical Site #20 | La Jolla | California | 92090 | — |
| Exelixis Clinical Site #46 | Los Angeles | California | 90025 | — |
| Exelixis Clinical Site #51 | Newport Beach | California | 92663 | — |
| Exelixis Clinical Site #62 | Santa Monica | California | 90404 | — |
| Exelixis Clinical Site #21 | Stanford | California | 94305 | — |
| Exelixis Clinical Site #34 | Denver | Colorado | 80218 | — |
| Exelixis Clinical Site #50 | Denver | Colorado | 80218 | — |
| Exelixis Clinical Site #42 | New Haven | Connecticut | 06511 | — |
| Exelixis Clinical Site #48 | Washington D.C. | District of Columbia | 20007 | — |
| Exelixis Clinical Site #16 | Jacksonville | Florida | 32224 | — |
| Exelixis Clinical Site #76 | Tampa | Florida | 33612 | — |
| Exelixis Clinical Site #60 | Atlanta | Georgia | 30318 | — |
| Exelixis Clinical Site #79 | Atlanta | Georgia | 30341 | — |
| Exelixis Clinical Site #32 | Harvey | Illinois | 60426 | — |
| Exelixis Clinical Site #23 | Fairway | Kansas | 66205 | — |
| Exelixis Clinical Site #57 | Lexington | Kentucky | 40536 | — |
| Exelixis Clinical Site #24 | New Orleans | Louisiana | 70112 | — |
| Exelixis Clinical Site #10 | Boston | Massachusetts | 02215 | — |
| Exelixis Clinical Site #3 | Detroit | Michigan | 48201 | — |
| Exelixis Clinical Site #17 | Rochester | Minnesota | 55905 | — |
| Exelixis Clinical Site #65 | Bolivar | Missouri | 65613 | — |
| Exelixis Clinical Site #43 | Kansas City | Missouri | 64111 | — |
| Exelixis Clinical Site #35 | Omaha | Nebraska | 68130 | — |
| Exelixis Clinical Site #59 | Omaha | Nebraska | 68130 | — |
| Exelixis Clinical Site #61 | Las Vegas | Nevada | 89169 | — |
| Exelixis Clinical Site #38 | Camden | New Jersey | 08103 | — |
| Exelixis Clinical Site #27 | East Brunswick | New Jersey | 08816 | — |
| Exelixis Clinical Site #31 | New Brunswick | New Jersey | 08903 | — |
| Exelixis Clinical Site #40 | East Setauket | New York | 11733 | — |
| Exelixis Clinical Site #11 | New York | New York | 10029 | — |
| Exelixis Clinical Site #37 | The Bronx | New York | 10461 | — |
| Exelixis Clinical Site #67 | Cleveland | Ohio | 44195 | — |
| Exelixis Clinical Site #49 | Columbus | Ohio | 43210 | — |
| Exelixis Clinical Site #64 | Kettering | Ohio | 45409 | — |
| Exelixis Clinical Site #71 | Oklahoma City | Oklahoma | 73104 | — |
| Exelixis Clinical Site #6 | Oklahoma City | Oklahoma | 73120 | — |
| Exelixis Clinical Site #102 | Portland | Oregon | 97213 | — |
| Exelixis Clinical Site #45 | Portland | Oregon | 97239 | — |
| Exelixis Clinical Site #41 | Bethlehem | Pennsylvania | 18015 | — |
| Exelixis Clinical Site #15 | Philadelphia | Pennsylvania | 19107 | — |
| Exelixis Clinical Site #55 | Philadelphia | Pennsylvania | 19111 | — |
| Exelixis Clinical Site #66 | Pittsburgh | Pennsylvania | 15232 | — |
| Exelixis Clinical Site #95 | Charleston | South Carolina | 29414 | — |
| Exelixis Clinical Site #13 | Dallas | Texas | 75246 | — |
| Exelixis Clinical Site #26 | Dallas | Texas | 75390 | — |
| Exelixis Clinical Site #114 | Fort Worth | Texas | 76104 | — |
| Exelixis Clinical Site #29 | Houston | Texas | 77030 | — |
| Exelixis Clinical Site #39 | Houston | Texas | 77030 | — |
| Exelixis Clinical Site #44 | Houston | Texas | 77030 | — |
| Exelixis Clinical Site #33 | Lubbock | Texas | 79410 | — |
| Exelixis Clinical Site #63 | San Antonio | Texas | 78229 | — |
| Exelixis Clinical Site #2 | Salt Lake City | Utah | 84112 | — |
| Exelixis Clinical Site #30 | Blacksburg | Virginia | 24060 | — |
| Exelixis Clinical Site #14 | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03170960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03170960 live on ClinicalTrials.gov.